Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Arch Cardiovasc Dis ; 115(2): 78-86, 2022 Feb.
Article in English | MEDLINE | ID: mdl-35115266

ABSTRACT

BACKGROUND: Myocardial infarction is a major cause of morbidity and mortality. Guidelines have been published to optimize medical care and involve optimization of the care pathway and hospital-city coordination. AIMS: To describe the myocardial infarction care pathway during the year following hospital discharge, and the use of and adherence to secondary prevention drugs. METHODS: A cohort study was conducted using data from the main French health insurance reimbursement database of the ex-Aquitaine region. Information about the medical and pharmaceutical care of hospitalized patients in 2018 was collected for 12 months. Medication adherence was assessed by using the proportion of days covered by the treatment and persistence. RESULTS: A total of 3015 patients were included, and the mean age was 66 years. Almost 76% of the patients had a reimbursement for BAS (combined prescription of beta-blocker/antiplatelet/lipid-lowering drug), BASI (combined prescription of beta-blocker/antiplatelet/lipid-lowering drug/angiotensin-converting enzyme inhibitor) or AS (combined prescription of antiplatelet/lipid-lowering drug) treatment. Medication adherence was around 83% for aspirin and 75% for lipid-lowering drugs for the 1-year persistence. During the same time, the proportion of days covered was suboptimal. Almost 4% of patients died after leaving hospital, 45% went to a cardiac rehabilitation centre and 23% had at least one hospital readmission, whatever the reason. Patients had a mean number of 11 general practitioner consultations during the year. Almost 41% of patients did not have a consultation with a cardiologist, and 38.4% had at least two consultations. Rehabilitation and general practitioner consultations were associated with adherence. CONCLUSIONS: These new results provide clear information on the medical care environment of patients, and help us to improve care transition. Close collaboration between healthcare practitioners is very important in the early stages of outpatient follow-up.


Subject(s)
Insurance, Health, Reimbursement , Myocardial Infarction , Aged , Cohort Studies , Critical Pathways , Humans , Medication Adherence , Myocardial Infarction/drug therapy , Prescriptions
2.
ESC Heart Fail ; 8(3): 2316-2319, 2021 06.
Article in English | MEDLINE | ID: mdl-33792203

ABSTRACT

A 72-year-old man daily suffered from a refractory angina consecutive to a diffuse coronary artery disease despite optimal medical management. Revascularization could not be performed because of a severe thrombopenia. He was referred to our outpatient cardiac rehabilitation programme where he was candidate for 20 sessions, three times a week, of high-intensity aerobic interval training involving brief episodes of regressive myocardial ischaemia. After 7 weeks, exercise capacity (+28.5%), VO2 peak (35.7%), and ischaemic threshold increased while clinical status and quality of life improved. No adverse effect was reported. Aerobic interval training with myocardial ischaemia might be a therapeutic alternative in refractory angina.


Subject(s)
Cardiac Rehabilitation , Coronary Artery Disease , Myocardial Ischemia , Aged , Angina Pectoris/diagnosis , Angina Pectoris/therapy , Humans , Male , Myocardial Ischemia/complications , Quality of Life
3.
Med Sci Sports Exerc ; 53(6): 1294-1302, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33433150

ABSTRACT

PURPOSE: A decision tree based on a clinicophysiological score (severe high-altitude illness (SHAI) score) has been developed to detect subjects susceptible to SHAI. We aimed to validate this decision tree, to rationalize the prescription of acetazolamide (ACZ), and to specify the rule for a progressive acclimatization. METHODS: Data were obtained from 641 subjects in 15 European medical centers before and during a sojourn at high altitude. Depending on the value of the SHAI score, advice was given and ACZ was eventually prescribed. The outcome was the occurrence of SHAI at high altitude as a function of the SHAI score, ACZ prescription, and use and fulfillment of the acclimatization rule. RESULTS: The occurrence of SHAI was 22.6%, similar to what was observed 18 yr before (23.7%), whereas life-threatening forms of SHAI (high-altitude pulmonary and cerebral edema) were less frequent (2.6%-0.8%, P = 0.007). The negative predictive value of the decision tree based was 81%, suggesting that the procedure is efficient to detect subjects who will not suffer from SHAI, therefore limiting the use of ACZ. The maximal daily altitude gain that limits the occurrence of SHAI was established at 400 m. The occurrence of SHAI was reduced from 27% to 12% when the recommendations for ACZ use and 400-m daily altitude gain were respected (P < 0.001). CONCLUSIONS: This multicenter study confirmed the interest of the SHAI score in predicting the individual risk for SHAI. The conditions for an optimized acclimatization (400-m rule) were also specified, and we proposed a rational decision tree for the prescription of ACZ, adapted to each individual tolerance to hypoxia.


Subject(s)
Acetazolamide/therapeutic use , Altitude Sickness/diagnosis , Altitude Sickness/prevention & control , Anticonvulsants/therapeutic use , Decision Trees , Acclimatization , Adult , Female , Humans , Male , Medication Adherence , Middle Aged , Risk Factors
6.
Int J Cardiol ; 299: 116-122, 2020 01 15.
Article in English | MEDLINE | ID: mdl-31405586

ABSTRACT

BACKGROUND: To assess the relationship between heart rate response and exercise tolerance in adults with systemic right ventricle (sRV) after atrial switch repair for Transposition of the Great Artery (TGA) in addition to other physiological parameters. METHODS: All patients with a sRV after atrial switch repair for TGA followed in our institution between June 2015 and April 2018 who underwent cardiopulmonary exercise testing (CPET) were analyzed. Cardiac imaging performed within a six-month time period of the CPET were also collected. Chronotropic incompetence was defined as the inability to achieve 80% of age-predicted maximal heart rate reserve (HRR) and <62% on a beta-blocker regimen. Patient characteristics were assessed according to tertiles of the percentage of predicted pVO2 (%ppVO2). RESULTS: We studied 70 patients (mean of age 32.4 ±â€¯7.6 years old, 51 males). Mean peak oxygen uptake was 21.5 ±â€¯5.8 mL/kg/min, corresponding to a %ppVO2 of 57 ±â€¯14.1% while mean VE/VCO2 slope was 37.1 ±â€¯8.2. There was a trend toward more exaggerated hyperventilation in patient with lower pVO2. Mean age-adjusted HRR was 68.5 ±â€¯19%. Chronotropic incompetence was observed in 65.7% and was correlated with %ppVO2 (r = 0.482; p < 0.001) as physical training evaluated with Ventilatory Anaerobic threshold (r = 0.571; p < 0.001), while no difference was found based on respiratory parameters. No echocardiographic or Magnetic Resonance Imaging parameters assessing sRV systolic function at rest were correlated with %ppVO2. CONCLUSIONS: Exercise limitation is related to the inability to increase cardiac output during exercise and is notably due to the degree of chronotropic incompetence.


Subject(s)
Arterial Switch Operation/trends , Exercise Test/methods , Exercise Tolerance/physiology , Heart Rate/physiology , Transposition of Great Vessels/diagnostic imaging , Transposition of Great Vessels/surgery , Adult , Female , Humans , Magnetic Resonance Imaging, Cine/methods , Male , Predictive Value of Tests , Retrospective Studies , Transposition of Great Vessels/physiopathology
8.
Arch Cardiovasc Dis ; 112(8-9): 459-468, 2019.
Article in English | MEDLINE | ID: mdl-31126738

ABSTRACT

BACKGROUND: Cardiac rehabilitation is strongly recommended in patients after acute myocardial infarction. AIMS: To assess cardiac rehabilitation prescription after acute myocardial infarction according to predicted risk, and its association with 1-year mortality, using the FAST-MI registries. METHODS: We used data from three 1-month French nationwide registries, conducted 5 years apart from 2005 to 2015, including 13130 patients with acute myocardial infarction admitted to coronary or intensive care units. Atherothrombotic risk stratification was performed using the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P). Patients were classified into three categories: Group 1 (low risk; no or one risk indicator; score of 0 or 1); Group 2 (intermediate risk; two risk indicators; score of 2); and Group 3 (high risk; at least three risk indicators; score of≥3). RESULTS: Among the 12291 patients, cardiac rehabilitation prescription was 43.6% (49.9% in Group 1; 43.0% in Group 2; 35.2% in Group 3). Using Cox multivariable analysis, cardiac rehabilitation prescription was associated with lower mortality at 1 year in the overall population (3.8% vs. 8.2%; hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.61-0.85; P<0.001). Cardiac rehabilitation was associated with improved 1-year mortality, with homogeneous relative risk reductions in low- and intermediate-risk categories (HR 0.70, 95% CI 0.51-0.94) compared with high-risk patients (HR 0.72, 95% CI 0.59-0.88). In absolute terms, however, mortality decrease associated with cardiac rehabilitation was positively correlated with risk level (Group 1, 0.9% vs. 2.4%; Group 2, 3.0% vs. 4.2%; Group 3, 10.5% vs. 17.3%). CONCLUSION: Cardiac rehabilitation prescription was inversely correlated with patient risk. A positive association between cardiac rehabilitation and 1-year survival after acute myocardial infarction was present whatever the risk level, but the greatest mortality reduction was observed in high-risk patients.


Subject(s)
Cardiac Rehabilitation , Non-ST Elevated Myocardial Infarction/rehabilitation , ST Elevation Myocardial Infarction/rehabilitation , Aged , Aged, 80 and over , Female , France , Humans , Male , Middle Aged , Non-ST Elevated Myocardial Infarction/diagnosis , Non-ST Elevated Myocardial Infarction/mortality , Non-ST Elevated Myocardial Infarction/physiopathology , Recovery of Function , Registries , Risk Assessment , Risk Factors , ST Elevation Myocardial Infarction/diagnosis , ST Elevation Myocardial Infarction/mortality , ST Elevation Myocardial Infarction/physiopathology , Time Factors , Treatment Outcome
9.
Diabetes Care ; 42(4): 674-681, 2019 04.
Article in English | MEDLINE | ID: mdl-30728222

ABSTRACT

OBJECTIVE: Acute glucose fluctuations are associated with hypoglycemia and are emerging risk factors for cardiovascular outcomes. However, the relationship between glycemic variability (GV) and the occurrence of midterm major cardiovascular events (MACE) in patients with diabetes remains unclear. This study investigated the prognostic value of GV in patients with diabetes and acute coronary syndrome (ACS). RESEARCH DESIGN AND METHODS: This study included consecutive patients with diabetes and ACS between January 2015 and November 2016. GV was assessed using SD during initial hospitalization. MACE, including new-onset myocardial infarction, acute heart failure, and cardiac death, were recorded. The predictive effects of GV on patient outcomes were analyzed with respect to baseline characteristics and cardiac status. RESULTS: A total of 327 patients with diabetes and ACS were enrolled. MACE occurred in 89 patients (27.2%) during a mean follow-up of 16.9 months. During follow-up, 24 patients (7.3%) died of cardiac causes, 35 (10.7%) had new-onset myocardial infarction, and 30 (9.2%) were hospitalized for acute heart failure. Multivariable logistic regression analysis showed that GV >2.70 mmol/L, a Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) score >34, and reduced left ventricular ejection fraction of <40% were independent predictors of MACE, with odds ratios (ORs) of 2.21 (95% CI 1.64-2.98; P < 0.001), 1.88 (1.26-2.82; P = 0.002), and 1.71 (1.14-2.54; P = 0.009), respectively, whereas a Global Registry of Acute Coronary Events (GRACE) risk score >140 was not (OR 1.07 [0.77-1.49]; P = 0.69). CONCLUSIONS: A GV cutoff value of >2.70 mmol/L was the strongest independent predictive factor for midterm MACE in patients with diabetes and ACS.


Subject(s)
Acute Coronary Syndrome/complications , Blood Glucose/analysis , Cardiovascular Diseases/etiology , Diabetes Complications , Diabetes Mellitus , Hospitalization , Humans , Percutaneous Coronary Intervention , Prognosis , Registries , Risk Factors
10.
Arch Cardiovasc Dis ; 112(1): 56-66, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30093255

ABSTRACT

The exercise test is performed routinely in cardiology; its main indication is the diagnosis of myocardial ischemia, evaluated along with the subject's pretest probability and cardiovascular risk level. Other criteria, such as analysis of repolarization, must be taken into consideration during the interpretation of an exercise test, to improve its predictive value. An exercise test is also indicated for many other cardiac diseases (e.g. rhythm and conduction disorders, severe asymptomatic aortic stenosis, hypertrophic cardiomyopathy, peripheral artery disease, hypertension). Moreover, an exercise test may be indicated for specific populations (women, the elderly, patients with diabetes mellitus, patients in a preoperative context, asymptomatic patients and patients with congenital heart defects). Some cardiac diseases (such as chronic heart failure or arterial pulmonary hypertension) require a cardiopulmonary exercise test. Finally, an exercise test or a cardiopulmonary exercise test is indicated to prescribe a cardiac rehabilitation programme, adapted to the patient.


Subject(s)
Cardiology/standards , Cardiorespiratory Fitness , Exercise Test/standards , Heart Diseases/diagnosis , Cardiac Rehabilitation , Clinical Decision-Making , Consensus , Exercise Tolerance , France , Heart Diseases/physiopathology , Heart Diseases/therapy , Humans , Predictive Value of Tests , Prognosis , Reproducibility of Results
11.
Arch Cardiovasc Dis ; 111(12): 782-790, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30093254

ABSTRACT

The exercise test is still a key examination in cardiology, used for the diagnosis of myocardial ischemia, as well as for the clinical evaluation of other heart diseases. The cardiopulmonary exercise test can further define functional capacity and prognosis for any given cardiac pathology. These new guidelines focus on methods, interpretation and indications for an exercise test or cardiopulmonary exercise test, as summarized below. The safety rules associated with the exercise test must be strictly observed. Interpretation of exercise tests and cardiopulmonary exercise tests must be multivariable. Functional capacity is a strong predictor of all-cause mortality and cardiovascular events. Chest pain, ST-segment changes and an abnormal ST/heart rate index constitute the first findings in favor of myocardial ischemia, mostly related to significant coronary artery disease. Chronotropic incompetence, abnormal heart rate recovery, QRS changes (such as enlargement or axial deviations) and the use of scores (based on the presence of various risk factors) must also be considered in exercise test interpretation for a coronary artery disease diagnosis. Arrhythmias or conduction disorders arising during the exercise test must be considered in the assessment of prognosis, in addition to a decrease or low increase in blood pressure during the exercise phase. When performing a cardiopulmonary exercise test, peak oxygen uptake and the volume of expired gas/carbon dioxide output slope are the two main variables used to evaluate prognosis.


Subject(s)
Cardiology/standards , Cardiovascular Diseases/diagnosis , Exercise Test/standards , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/therapy , Consensus , Exercise Test/adverse effects , Exercise Tolerance , France , Hemodynamics , Humans , Predictive Value of Tests , Prognosis , Reproducibility of Results , Respiration
12.
Sante Publique ; 30(5): 689-695, 2018.
Article in French | MEDLINE | ID: mdl-30767484

ABSTRACT

INTRODUCTION: Laboratory tests usually complete clinical examinations for diagnostic, prognostic and even therapeutical care. However, French doctors might too easily prescribe such examinations without knowing their cost. As a matter of fact, the prescription is sometimes excessive or unjustified. Cardiology is not an exception, with costly laboratory tests. OBJECTIVE: To show that the relevance of each additional test prescription, in a cardiology department, allows a significant reduction of the examination volumes and costs, with no prejudicial effect on patients' care. METHODS: Two consecutive 2-year periods, between November 1st 2011 and October 31st 2015, - before and after the development of a policy of rationalization of additional tests - were compared. All the patients admitted in our cardiology department during these periods were prospectively included.During 4 years, the volume and the cost of prescription of the most frequent laboratory tests were studied, considering successive half-year periods. RESULTS: After rationalizing, there was a significant reduction of prescription of the laboratory tests (CBC -72%, BNP -92%, troponin -82%, CRP -89%, liver test -87%, lipid status -80%, TSH -80%, p<0.01).No serious adverse events were reported and no death rate increase was noticed. CONCLUSION: Rationalizing allows a significant reduction of complementary examinations, with no additional risk for the patient.


Subject(s)
Cardiology Service, Hospital , Clinical Laboratory Techniques/statistics & numerical data , Rationalization , Clinical Laboratory Techniques/economics , Costs and Cost Analysis , France , Humans , Prospective Studies , Risk Assessment
14.
Eur Heart J ; 37(4): 365-74, 2016 Jan 21.
Article in English | MEDLINE | ID: mdl-26364288

ABSTRACT

AIM: This open-label, randomized, and multicentre trial tested the hypothesis that, on a background of aspirin, continuing clopidogrel would be superior to stopping clopidogrel at 12 months following drug-eluting stent (DES) implantation. METHODS AND RESULTS: Patients (N = 1799) who had undergone placement of ≥1 DES for stable coronary artery disease or acute coronary syndrome were included in 58 French sites (January 2009-January 2013). Patients (N = 1385) free of major cardiovascular/cerebrovascular events or major bleeding and on aspirin and clopidogrel 12 months after stenting were eligible for randomization (1:1) between continuing clopidogrel 75 mg daily (extended-dual antiplatelet therapy, DAPT, group) or discontinuing clopidogrel (aspirin group). The primary outcome was net adverse clinical events defined as the composite of death, myocardial infarction, stroke, or major bleeding. Follow-up was planned from a minimum of 6 to a maximum of 36 months after randomization. Owing to slow recruitment, the study was stopped after enrolment of 1385 of a planned 1966 patients. Median follow-up after stenting was 33.4 months. The primary outcome occurred in 40 patients (5.8%) in the extended-DAPT group and 52 in the aspirin group (7.5%; hazard ratio 0.75, 95% confidence interval 0.50-1.28; P = 0.17). Rates of death were 2.3% in the extended-DAPT group and 3.5% in the aspirin group (HR 0.65, 95% CI 0.34-1.22; P = 0.18). Rates of major bleeding were identical (2.0%, P = 0.95). CONCLUSIONS: Extended DAPT did not achieve superiority in reducing net adverse clinical events compared to 12 months of DAPT after DES placement. The power of the OPTIDUAL trial was however low and reduced by premature termination of enrolment. CLINICALTRIALSGOV NUMBER: NCT00822536.


Subject(s)
Acute Coronary Syndrome/drug therapy , Coronary Artery Disease/drug therapy , Drug-Eluting Stents , Platelet Aggregation Inhibitors/administration & dosage , Ticlopidine/analogs & derivatives , Acute Coronary Syndrome/mortality , Adult , Aftercare , Clopidogrel , Coronary Artery Disease/mortality , Drug Administration Schedule , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Ticlopidine/administration & dosage , Treatment Outcome
15.
Arch Cardiovasc Dis ; 109(3): 178-87, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26711546

ABSTRACT

BACKGROUND: Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality. OBJECTIVE: To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI). METHODS: Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model. RESULTS: At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were younger (62.4 vs. 67.5years), were more frequently men and more had presented with STEMI (67.8% vs. 48.3%) than non-referred patients. Ninety-four (14.7%) deaths occurred among patients referred to CR and 585 (25.9%) among non-referred patients (P<0.001). After multivariable adjustment, the association between CR and mortality remained significant (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.60-0.96). Analyses stratified by sex, age (<60 vs.≥60years) and AMI type showed that the inverse association was stronger in men (HR 0.64, 95% CI 0.48-0.87) than in women (HR 0.95, 95% CI 0.64-1.39), in younger (HR 0.34, 95% CI 0.15-0.77) than in older patients (HR 0.84, 95% CI 0.65-1.07) and in NSTEMI (HR 0.63, 95% CI 0.46-0.88) than in STEMI (HR 0.99, 95% CI 0.69-1.40). CONCLUSION: After hospitalization for AMI, referral to CR remains a significant predictor of improved patient survival; some subgroups seem to gain greater benefit.


Subject(s)
Acute Coronary Syndrome/mortality , Acute Coronary Syndrome/rehabilitation , Myocardial Infarction/mortality , Myocardial Infarction/rehabilitation , Acute Coronary Syndrome/diagnosis , Aged , Chi-Square Distribution , Female , Follow-Up Studies , France , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/diagnosis , Patient Discharge , Proportional Hazards Models , Prospective Studies , Referral and Consultation , Registries , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
16.
J Electrocardiol ; 48(5): 879-86, 2015.
Article in English | MEDLINE | ID: mdl-26228931

ABSTRACT

BACKGROUND: A new ECG criterion has been studied in Brugada syndrome (BrS) at rest to differentiate type 2 and incomplete right bundle branch block (IRBBB). METHODS: We assessed this criterion during exercise comparing BrS (46 patients) and IRBBB (17 patients). A beta angle was measured from lead V1 between the upslope of S-wave and the downslope of the r'-wave. RESULTS: Beta angle was significantly larger in BrS at rest (58±24° vs 25±15°, p<0.001), exercise (47±26° vs 15±11°, p<0.001), and recovery (46±24° vs 21±12°, p<0.001) with a reduction in angle at exercise compared to rest. There was a significant rebound in angle at recovery in the control group to (p<0.001); no such rebound was observed in the BrS group (p=NS). CONCLUSION: Beta angle study at rest and its evolution at exercise could help discriminate BrS patients from healthy subjects.


Subject(s)
Algorithms , Brugada Syndrome/diagnosis , Diagnosis, Computer-Assisted/methods , Electrocardiography/methods , Exercise Test/methods , Brugada Syndrome/classification , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
17.
BMC Cardiovasc Disord ; 15: 64, 2015 Jul 08.
Article in English | MEDLINE | ID: mdl-26152221

ABSTRACT

BACKGROUND: Gain in VO2 peak after cardiac rehabilitation (CR) following an acute coronary syndrome (ACS), is associated with reduced mortality and morbidity. We have previously shown in CR, that gain in VO2 peak is reduced in Type 2 diabetic patients and that response to CR is impaired by hyperglycemia. METHODS: We set up a prospective multicenter study (DARE) whose primary objective was to determine whether good glycemic control during CR may improve the gain in VO2 peak. Sixty four type 2 diabetic patients, referred to CR after a recent ACS, were randomized to insulin intensive therapy or a control group with continuation of the pre-CR antidiabetic treatment. The primary objective was to study the effect of glycemic control during CR on the improvement of peak VO2 by comparing first the 2 treatment groups (insulin intensive vs. control) and second, 2 pre-specified glycemic control groups according to the final fructosamine level (below and above the median). RESULTS: At the end of the CR program, the gain in VO2 peak and the final fructosamine level (assessing glycemic level during CR) were not different between the 2 treatment groups. However, patients who had final fructosamine level below the median value, assessing good glycemic control during CR, showed significantly higher gain in VO2 peak (3.5 ± 2.4 vs. 1.7 ± 2.4 ml/kg/min,p = 0.014) and ventilatory threshold (2.7 ± 2.5 vs. 1.2 ± 1.9 ml/kg/min,p = 0.04) and a higher proportion of good CR-responders (relative gain in VO2 peak ≥ 16 %): 66 % vs. 36 %, p = 0.011. In multivariate analysis, gain in VO2 peak was associated with final fructosamine level (p = 0.010) but not with age, gender, duration of diabetes, type of ACS, insulin treatment or basal fructosamine. CONCLUSIONS: The DARE study shows that, in type 2 diabetes, good glycemic control during CR is an independent factor associated with gain in VO2 peak. This emphasizes the need for good glycemic control in CR for type 2 diabetic patients. TRIAL REGISTRATION: Trial registered as NCT00354237 (19 July 2006).


Subject(s)
Acute Coronary Syndrome/rehabilitation , Diabetes Mellitus, Type 2/drug therapy , Exercise Therapy/methods , Hypoglycemic Agents/therapeutic use , Insulin Aspart/therapeutic use , Insulin Glargine/therapeutic use , Oxygen Consumption , Acute Coronary Syndrome/complications , Aged , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/metabolism , Female , Fructosamine/metabolism , Glycated Hemoglobin/metabolism , Humans , Male , Metformin/therapeutic use , Middle Aged , Pulmonary Gas Exchange , Pulmonary Ventilation , Treatment Outcome
18.
Rev Prat ; 65(3): 357-8, 360-2, 2015 Mar.
Article in French | MEDLINE | ID: mdl-26016195

ABSTRACT

Shortening the hospitalization period during an acute coronary syndrome can lead to a trivialization of the event, and especially causes many questions among patients about their future lifestyle. A secondary medical care in rehabilitation centers allows to combine the numerous benefits of physical training and to answer to their questioning, through to both a collective and individual therapeutic education.


Subject(s)
Coronary Artery Disease/rehabilitation , Life Style , Coronary Artery Disease/drug therapy , Humans , Length of Stay , Patient Education as Topic , Return to Work , Risk Reduction Behavior , Sexual Behavior
19.
Arch Cardiovasc Dis ; 107(1): 33-41, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24440004

ABSTRACT

BACKGROUND: Heart rate is a major determinant of myocardial oxygen demand; in ST-segment elevation myocardial infarction (STEMI), patients treated with primary percutaneous intervention (PPCI), heart rate at discharge correlates with mortality. Ivabradine is a pure heart rate-reducing agent that has no effect on blood pressure and contractility, and can reverse left ventricular (LV) remodelling in patients with heart failure. AIMS: To evaluate whether ivabradine, when added to current guideline-based therapy, improves LV remodelling in STEMI patients treated with PPCI. METHODS: This paired-cohort study included 124 patients between June 2011 and July 2012. Ivabradine (5mg twice daily) was given promptly after PPCI, along with beta-blockers, to obtain a heart rate<60 beats per minute (ivabradine group). This group was matched with STEMI patients treated in line with current guidelines, including beta-blockers (bisoprolol), according to age, sex, infarct-related coronary artery, ischaemia time and infarct size determined by initial cardiac magnetic resonance imaging (CMR) (control group). Statistical analyses were performed according to an intention-to-continue treatment principle. CMR data at 3 months were available for 122 patients. RESULTS: Heart rate was lower in the ivabradine group than in the control group during the initial CMR (P=0.02) and the follow-up CMR (P=0.006). At the follow-up CMR, there was a smaller increase in LV end-diastolic volume index in the ivabradine group than in the control group (P=0.04). LV end-systolic volume index remained unchanged in the ivabradine group, but increased in the control group (P=0.01). There was a significant improvement in LV ejection fraction in the ivabradine group compared with in the control group (P=0.04). CONCLUSIONS: In successfully reperfused STEMI patients, ivabradine may improve LV remodelling when added to current guideline-based therapy.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Benzazepines/therapeutic use , Heart Rate/drug effects , Myocardial Infarction/therapy , Percutaneous Coronary Intervention , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Adrenergic beta-Antagonists/therapeutic use , Aged , Drug Therapy, Combination , Feasibility Studies , Female , Humans , Ivabradine , Magnetic Resonance Imaging , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/physiopathology , Myocardium/pathology , Percutaneous Coronary Intervention/adverse effects , Pilot Projects , Practice Guidelines as Topic , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...